Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
2.360
-0.070 (-2.88%)
Feb 21, 2025, 4:00 PM EST - Market closed
Tango Therapeutics Stock Forecast
TNGX's stock price has decreased by -79.88% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Tango Therapeutics stock have an average target of 13.14, with a low estimate of 8.00 and a high estimate of 19. The average target predicts an increase of 456.78% from the current stock price of 2.36.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 11, 2024.
Analyst Ratings
The average analyst rating for Tango Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
Buy | 4 | 4 | 4 | 4 | 4 | 4 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Dec 5, 2024 |
B. Riley Securities | B. Riley Securities | Strong Buy Maintains $16 → $8 | Strong Buy | Maintains | $16 → $8 | +238.98% | Nov 11, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +450.85% | Nov 8, 2024 |
Guggenheim | Guggenheim | Strong Buy Maintains $18 → $8 | Strong Buy | Maintains | $18 → $8 | +238.98% | Nov 7, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +450.85% | Oct 28, 2024 |
Financial Forecast
Revenue This Year
46.66M
from 36.53M
Increased by 27.73%
Revenue Next Year
28.97M
from 46.66M
Decreased by -37.90%
EPS This Year
-1.22
from -1.08
EPS Next Year
-1.45
from -1.22
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | 56.3M | 45.6M | 45.6M | |||
Avg | 46.7M | 29.0M | 25.5M | |||
Low | 42.1M | 19.6M | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | 54.1% | -2.2% | 57.5% | |||
Avg | 27.7% | -37.9% | -12.0% | |||
Low | 15.2% | -58.0% | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | -1.17 | -1.27 | -1.28 | |||
Avg | -1.22 | -1.45 | -1.49 | |||
Low | -1.23 | -1.51 | -1.59 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.